Literature DB >> 8173849

A gastroscopic study of the predictive value of risk factors for non-steroidal anti-inflammatory drug-associated ulcer disease in rheumatoid arthritis patients.

M Janssen1, B A Dijkmans, C B Lamers, A H Zwinderman, J P Vandenbroucke.   

Abstract

Peptic ulcer disease (PUD) in RA patients is associated with NSAID use. This study aimed to validate the predictive value of presumed risk factors for NSAID-associated PUD in a prospective gastroscopic study in RA patients. Eighty-one NSAID using RA patients were prospectively divided into four presumed risk groups according to Helicobacter pylori status and history of PUD. As additional risk factors the following were analysed: upper gastrointestinal GI complaints; disability; daily dose of NSAID and antral gastritis. The presence of PUD in the four risk groups did not differ. Additionally it was found that a history of PUD was predictive for current PUD [odds ratio (OR) 3.9; 95% CI 1.1-14]. H. pylori status was not predictive. Transformation from one ulcer type to another was rare. NSAID dose was not a risk factor, while disability was of borderline importance (OR 2.1; 95% CI 1-4.8). Current upper GI complaints were bad predictors. PUD only occurred with a concomitant antral gastritis. A history of PUD, disability and antral gastritis were the most important predictors for current PUD. When an ulcer relapsed it was of the same ulcer type as had been present earlier. This may have practical implications for prophylaxis enabling stratification by previous ulcer type.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8173849     DOI: 10.1093/rheumatology/33.5.449

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  8 in total

Review 1.  [Risk of ulcer and its prophylaxis in therapy with non-steroidal antirheumatic drugs].

Authors:  L Köhler; W Mau; H Zeidler
Journal:  Med Klin (Munich)       Date:  1997-12-15

2.  Are altered pharmacokinetics of non-steroidal anti-inflammatory drugs (NSAIDs) a risk factor for gastrointestinal bleeding?

Authors:  H A Wynne; A Long; E Nicholson; A Ward; D Keir
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

3.  The effect of ranitidine on NSAID related dyspeptic symptoms with and without peptic ulcer disease of patients with rheumatoid arthritis and osteoarthritis.

Authors:  J H Van Groenendael; H M Markusse; B A Dijkmans; F C Breedveld
Journal:  Clin Rheumatol       Date:  1996-09       Impact factor: 2.980

Review 4.  Misoprostol/NSAID fixed combinations. Help or hindrance in clinical practice?

Authors:  A Isdale; V Wright
Journal:  Drug Saf       Date:  1995-05       Impact factor: 5.606

Review 5.  Therapy and prevention of gastric ulcer.

Authors:  C B Lamers; I Biemond; A A Masclee; R A Veenendaal
Journal:  Yale J Biol Med       Date:  1996 May-Jun

Review 6.  From peptic ulcer disease to NSAID gastropathy. An evolving nosology.

Authors:  S H Roth
Journal:  Drugs Aging       Date:  1995-05       Impact factor: 3.923

7.  Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects.

Authors:  Jeroen C F de Jong; Paul B van den Berg; Hilde Tobi; Lolkje T W de Jong-van den Berg
Journal:  Br J Clin Pharmacol       Date:  2003-06       Impact factor: 4.335

Review 8.  Helicobacter pylori and non-steroidal anti-inflammatory drugs: does infection affect the outcome of NSAID therapy?

Authors:  D M McCarthy
Journal:  Yale J Biol Med       Date:  1998 Mar-Apr
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.